CTNND2

Across TCGA pan-cancer cohorts, CTNND2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of CTNND2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CTNND2 RNA is repressed in tumor relative to normal tissue. In most cancer types CTNND2 is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

KIRC, COAD, and LUAD are the cancer types where CTNND2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CTNND2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	−0.458	<.001	12	view →
COAD	Male	II,III,IV	−0.741	<.001	11	view →
LUAD	Female	III,IV	−1.840	<.001	9	view →
BRCA	All	II,III,IV	+0.461	.015	8	view →
LUSC	Female	II,III,IV	−1.862	<.001	6	view →
UCEC	All	All	+1.106	.005	6	view →
READ	Female	All	−1.136	<.001	5	view →
KIRP	Male	All	−0.328	<.001	4	view →
HNSC	All	All	−0.231	.012	4	view →
CHOL	All	All	+3.401	<.001	3	view →
LIHC	Female	All	+1.040	.021	3	view →
KICH	Female	III,IV	−0.479	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

CTNND2–KIRC

Open the KIRC breakdown →